Public Release: 

Different methods of adjuvant chemotherapy for colorectal cancer have similar outcomes

Journal of the National Cancer Institute

Colorectal cancer patients who receive fluorouracil-based adjuvant chemotherapy have similar survival rates whether the chemotherapy is delivered systemically (by vein or by mouth), regionally (to a specific area of the body), or by a combined regimen of both methods, according to a new study, which appears in the May 19 issue of the Journal of the National Cancer Institute.

Each year, about one million people worldwide are diagnosed with colorectal cancer and about half that number dies from the disease. After colon tumors are removed surgically, many patients are treated with fluorouracil-based adjuvant chemotherapy. Whether the chemotherapy should be delivered via the systemic or regional methods, however, has been controversial.

To test the effectiveness of both methods of chemotherapy, Roberto Labianca, M.D., of the Ospedali Riuniti in Bergamo, Italy, and colleagues conducted a randomized clinical trial of 1084 patients with colon carcinoma in Dukes' stage B or C who were recruited between 1992 and 1998. After surgery, the patients received the regional regimen, the systemic regimen, or regional followed by systemic chemotherapy.

Survival rates after 5 years--74% for the regional regimen, 78% for the systemic regimen, and 73% for the combination--were similar for all three groups, as were rates of survival without recurrences or second malignancies. However, only 9% of patients who received the regional regimen experienced an adverse reaction to the chemotherapy compared with 47% who received the systemic regimen.

"The main result of this study is that the combination [systemic plus regional] regimen did not provide an additive benefit and, in fact, was similar to that of the chemotherapy delivered by either the [regional] regimen or the [systemic] regimen alone. Overall survival and event-free survival rates were similar among all three groups," the authors write.

In an editorial, Jean L. Grem, M.D., of the University of Nebraska Medical Center in Omaha, discusses the difficulty in studying the various regimens of adjuvant chemotherapy available for treating colorectal cancer. She concludes that, "The clinical research strategy for the adjuvant therapy of colon cancer must be focused, yet flexible, to accommodate the evolving status of available novel therapies."

###

Contacts:

  • Article: Claudia Rota, Media Office, Ospedali Riuniti, crota@ospedaliriuniti.bergamo.it, or Isabella Bordogna, Media Office, Mario Negri Institute, 39-023-901-4581, bordogna@marionegri.it
  • Editorial: Tom O'Connor, UNMC Public Affairs, 402-559-4690, toconnor@unmc.edu

    Citations:

  • Article: Labianca R, Fossati R, Zaniboni A, Torri V, Marsoni S, Nitti D, et al. Randomized Trial of Intraportal and/or Systemic Adjuvent Chemotherapy in Patients With Colon Carcinoma. J Natl Cancer Inst 2004;96:750-8.
  • Editorial: Grem JL. Mature Results of Adjuvant Colon Cancer Trials From the Fluorouracil-Only Era. J Natl Cancer Inst 2004;96:727-9.

    Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oupjournals.org/.

  • Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.